Matthew R. Farren

1.8k total citations
34 papers, 1.3k citations indexed

About

Matthew R. Farren is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Matthew R. Farren has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Immunology. Recurrent topics in Matthew R. Farren's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Matthew R. Farren is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Matthew R. Farren collaborates with scholars based in United States, United Kingdom and Austria. Matthew R. Farren's co-authors include Kelvin P. Lee, Gregory B. Lesinski, Colleen S. Netherby, Scott I. Abrams, Thomas A. Mace, Kebin Liu, Qiang Hu, Paul N. Bogner, Song Liu and Austin Miller and has published in prestigious journals such as Journal of Clinical Investigation, Blood and The Journal of Immunology.

In The Last Decade

Matthew R. Farren

32 papers receiving 1.3k citations

Peers

Countries citing papers authored by Matthew R. Farren

Since Specialization

Citations

This map shows the geographic impact of Matthew R. Farren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew R. Farren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew R. Farren more than expected).

Fields of papers citing papers by Matthew R. Farren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew R. Farren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew R. Farren. The network helps show where Matthew R. Farren may publish in the future.

Co-authorship network of co-authors of Matthew R. Farren

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew R. Farren. A scholar is included among the top collaborators of Matthew R. Farren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew R. Farren. Matthew R. Farren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer 2025 ·PLoS ONE ·(unknown), Margaret Favata, Michaël Weber, (unknown), (unknown), K. D. Hammond, Matthew R. Farren, (unknown), Aidan G. Gilmartin, Hui Wang, Jonathan Rios‐Doria, Alejandro Amador‐Arjona	0
2	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186 2021 ·Cancer Immunology Immunotherapy ·Cameron J. Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O’Neil, Tanios Bekaii‐Saab, Anne M. Noonan, Christopher McQuinn, Thomas A. Mace, Walid L. Shaib, Christina Wu, Bassel F. El‐Rayes, Safi Shahda, Gregory B. Lesinski	23
3	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer 2020 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Mohammad Y. Zaidi, (unknown), Brian M. Olson, (unknown), Matthew R. Farren, Ganji Purnachandra Nagaraju, Chao Zhang, Zhengjia Chen, Juan M. Sarmiento, Rafi Ahmed, Shishir K. Maithel, Bassel F. El‐Rayes, Gregory B. Lesinski	39
4	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease 2020 ·British Journal of Cancer ·(unknown), Mohammad Y. Zaidi, Jennifer Yang, (unknown), Alyssa M. Krasinskas, Thomas A. Mace, (unknown), Matthew R. Farren, (unknown), Yiman Li, Chao Zhang, Zhengjia Chen, Gregory Young, (unknown), (unknown), Shishir K. Maithel, Tanios Bekaii‐Saab, Bassel F. El‐Rayes, Gregory B. Lesinski	5
5	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy 2019 ·JCI Insight ·Matthew R. Farren, (unknown), (unknown), Hsiao-Rong Chen, Jingjing Gong, Yan Liang, Alyssa M. Krasinskas, Shishir K. Maithel, Mohammad Y. Zaidi, Juan M. Sarmiento, David A. Kooby, Pretesh Patel, Bassel F. El‐Rayes, Walid L. Shaib, Gregory B. Lesinski	41
6	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function 2019 ·Scientific Reports ·Thomas A. Mace, (unknown), (unknown), Shannon Loftus, Matthew R. Farren, Elizabeth L. McMichael, Steven D. Scoville, (unknown), Gregory Young, William E. Carson, Steven K. Clinton, Gregory B. Lesinski	54
7	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors 2017 ·Molecular Cancer Therapeutics ·Matthew R. Farren, (unknown), Reena Shakya, (unknown), Gregory Young, Kari Kendra, Yosef Landesman, Sivan Elloul, Marsha Crochiere, Boris Klebanov, Trinayan Kashyap, Christin E. Burd, Gregory B. Lesinski	23
8	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment 2017 ·Cancer Research ·(unknown), Agnieszka Świdnicka‐Siergiejko, (unknown), Myrriah Chavez-Tomar, Gregory B. Lesinski, Tanios Bekaii‐Saab, Matthew R. Farren, Thomas A. Mace, Carl Schmidt, Yan Liu, Defeng Deng, Rosa F. Hwang, Liran Zhou, Todd T. Moore, Deyali Chatterjee, Huamin Wang, Xiaohong Leng, Ralph B. Arlinghaus, Craig D. Logsdon, Zobeida Cruz‐Monserrate	114
9	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities 2016 ·Molecular Cancer Therapeutics ·Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory Young, (unknown), (unknown), Cynthia Timmers, Priyani Rajasekera, (unknown), Mark Bloomston, Tanios Bekaii‐Saab, Denis C. Guttridge, Gregory B. Lesinski	29
10	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma 2016 ·Molecular Therapy ·Anne M. Noonan, Matthew R. Farren, Susan Geyer, Ying Huang, Sanaa Tahiri, Daniel H. Ahn, Sameh Mikhail, Kristen K. Ciombor, Shubham Pant, Santiago Aparo, Jennifer Sexton, John L. Marshall, Thomas A. Mace, Christina Wu, Bassel F. El‐Rayes, Cynthia Timmers, James A. Zwiebel, Gregory B. Lesinski, Miguel A. Villalona‐Calero, Tanios Bekaii‐Saab	119
11	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer 2015 ·Clinical Cancer Research ·Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen K. Ciombor, Sanaa Tahiri, Daniel H. Ahn, Anne M. Noonan, Miguel A. Villalona‐Calero, Tanios Bekaii‐Saab, Gregory B. Lesinski	69
12	Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer 2015 ·Cell Metabolism ·Aurélien Pommier, Matthew R. Farren, Bhavika Patel, Mark Wappett, Filippos Michopoulos, Neil R. Smith, Jane Kendrew, (unknown), R. Huby, Catherine A. Eberlein, (unknown), Christopher J. Womack, Paul Smith, Jane Robertson, Shethah Morgan, Susan E. Critchlow, Simon T. Barry	15
13	Stressful Presentations: Mild Cold Stress in Laboratory Mice Influences Phenotype of Dendritic Cells in Naïve and Tumor-Bearing Mice 2014 ·Frontiers in Immunology ·Kathleen M. Kokolus, (unknown), Benjamin Povinelli, Matthew R. Farren, Kelvin P. Lee, Elizabeth A. Repasky	53
14	E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling 2014 ·Oncogene ·Catherine A. Eberlein, Claire Rooney, Sarah J. Ross, Matthew R. Farren, Hazel M. Weir, Simon T. Barry	42
15	Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy 2013 ·Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Matthew R. Farren, Aurélien Pommier, Ruth Swann, Xin Wang, (unknown), Karen McDaid, Jane Kendrew, Chris Womack, Stephen R. Wedge, Simon T. Barry	111
16	Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7 2013 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Christina Bade‐Doeding, (unknown), (unknown), Matthew R. Farren, Kelvin P. Lee, Rainer Blasczyk, Trevor Huyton	5
17	RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib 2013 ·PLoS ONE ·James Bradford, Matthew R. Farren, Steve Powell, Sarah Runswick, Susie Weston, Helen Brown, Oona Delpuech, Mark Wappett, Neil R. Smith, T. Hedley Carr, Jonathan R. Dry, Neil Gibson, Simon T. Barry	24
18	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis 2013 ·Journal of Clinical Investigation ·Jeremy D. Waight, Colleen S. Netherby, Mary L. Hensen, Austin Miller, Qiang Hu, Song Liu, Paul N. Bogner, Matthew R. Farren, Kelvin P. Lee, Kebin Liu, Scott I. Abrams	263
19	Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies 2012 ·Angiogenesis ·Matthew R. Farren, Susie Weston, Helen Brown, (unknown), Steve Powell, Robert A. Shaw, Neil R. Smith, (unknown), (unknown), Sue Ashton, Stephen R. Wedge, Simon T. Barry	6
20	Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression 2009 ·Immunologic Research ·Matthew R. Farren, Louise Carlson, Kelvin P. Lee	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact